Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie Acquires 5,000 Shares

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie acquired 5,000 shares of Septerna stock in a transaction that occurred on Friday, February 21st. The shares were purchased at an average cost of $5.85 per share, with a total value of $29,250.00. Following the completion of the acquisition, the chief financial officer now owns 30,000 shares of the company’s stock, valued at $175,500. The trade was a 20.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Stock Down 1.5 %

Shares of NASDAQ SEPN opened at $5.80 on Friday. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99. The stock has a 50-day moving average of $17.78.

Institutional Investors Weigh In On Septerna

Several institutional investors and hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. purchased a new stake in shares of Septerna in the fourth quarter worth about $160,205,000. TRV GP V LLC purchased a new stake in shares of Septerna in the fourth quarter worth about $142,337,000. TRV GP VI LLC acquired a new position in shares of Septerna in the fourth quarter worth about $72,191,000. Samsara BioCapital LLC acquired a new position in shares of Septerna in the fourth quarter worth about $63,399,000. Finally, Driehaus Capital Management LLC acquired a new position in shares of Septerna in the fourth quarter worth about $59,301,000.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target for the company. TD Cowen assumed coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th. Finally, Wells Fargo & Company downgraded Septerna from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $43.00 to $14.00 in a research report on Tuesday.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.